✦ LIBER ✦

A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients

✍ Scribed by Ichraf Kraoua; Frédéric Sedel; Catherine Caillaud; Roseline Froissart; Jérôme Stirnemann; Guy Chaurand; Hugues Flodrops; Saliha Tari; Isabelle Gourfinkel-An; Sophie Mathieu; Nadia Belmatoug; Thierry Billette de Villemeur; Cyril Mignot

Book ID: 113498878
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 138 KB
Volume: 33
Category: Article
ISSN: 0387-7604
DOI: 10.1016/j.braindev.2010.02.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neurological outcome of a patient with G

Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy

✍ D. Dobbelaere; S. Sukno; S. Defoort-Dhellemmes; M.-D. Lamblin; C. Largillière 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 106 KB

Outcome of enzyme replacement therapy in

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

✍ P. Grigorescu Sido; C. Drugan; V. Cret; C. Al-Kzouz; C. Denes; C. Coldea; A. Zim 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 299 KB

‘Non-neuronopathic’ Gaucher disease reco

‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature

✍ M. Biegstraaten; I. N. van Schaik; J. M. F. G. Aerts; C. E. M. Hollak 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 371 KB

Mutation analysis of the acid β-glucosid

Mutation analysis of the acid β-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase

✍ Dominique P. Germain; Christine R. Kaneski; Roscoe O. Brady 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Frequency, phenotype, outcome, and thera

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

✍ Daniel C. Baumgart; Ulrike Grittner; Andrea Steingräber; Marina Azzaro; Sandra P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Background: The monoclonal anti tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (

Frequency, Phenotype, Outcome and Therap

Frequency, Phenotype, Outcome and Therapeutic Impact of Skin Reactions Following Initiation of Adalimumab Therapy: Experience From a Consecutive Cohort of Inflammatory Bowel Disease Patients

✍ Baumgart, Daniel C. ;Grittner, Ulrike ;Steingräber, Andrea ;Azzaro, Marina ;Phil 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB